This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: May 14, 2003
Last updated: January 11, 2017
Last verified: October 2016
The purpose of this pilot study is to examine the effects of combined pharmacotherapy (Zyban/NRT)/behavioral treatment on smoking cessation among methadone maintenance therapy patients.

Condition Intervention Phase
Tobacco Use Disorder Other: Combined intervention Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study Examining the Effects of Combined Pharmacotherapy (Zyban/NRT)/Behavioral Treatment on Smoking Cessation Among MMT Patients.

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Behavioral [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Number of cigarettes smoked per day [ Time Frame: six months ]

Enrollment: 28
Study Start Date: June 2002
Study Completion Date: December 2002
Primary Completion Date: September 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Combined Pharmacotherapy and Counseling
300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
Other: Combined intervention
300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling

Detailed Description:
This is a one-arm, open label pilot study of MMT patients to determine whether bupropion, nicotine replacement therapy, and behavioral counseling is a feasible and potentially effective intervention for smoking cessation. The smoking behaviors of participants will be be followed for 6 months post quit-date to determine effect-size estimates for a future, large scale trial.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients in long-term methadone maintenance treatment
  • Patient smokes at least 10 cigarettes per day, are stable on their use of methadone (phase 2 or higher treatment), smoked for at least 1 year, be willing to participate for 6 months, and not have used bupropion or nicotine replacement therapy for 6 months

Exclusion Criteria:

  • Patients who use prescription drug regimens that might affect methadone or bupropion metabolism
  • Patients with cardiovascular disease, asthma, COPD
  • Patients who are pregnant or breastfeeding
  • Patients with regular use of alcohol, other illicit drugs, or other types of tobacco (chewing or pipe for example)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00060814

United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160 7420
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Kimber Richter, Ph.D. University of Kansas Medical Center
  More Information

Responsible Party: Kimber Richter, PhD, University of Kansas Medical Center Identifier: NCT00060814     History of Changes
Other Study ID Numbers: NIDA-00450-2
Study First Received: May 14, 2003
Last Updated: January 11, 2017

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on August 22, 2017